V01AH05 - Antithrombotic agents. Pharmacotherapeutic group: V01AV04 - Antithrombotic agents. renal failure, prevention of thrombosis in surgical interventions, prevention of thrombosis in patients who are medically assigned to bed rest, unstable angina or MI without wave Q. Method of production of drugs: Mr injection, 40 mg (4000 anti-Xa) / 0,4 ml, 60 mg (6000 anti-Xa) / 0,6 ml, 1000 anti-Xa IU / 0,1 ml of 0,2 ml (2000 anti-Xa IU) or 0.4 ml (4000 anti-Xa Slips made out or 0.8 ml (8000 anti-Xa IU). Indications for use drugs: prevention of venous hazelnut in patients after major orthopedic operations on the lower extremities, including hip fractures (including prolonged prophylaxis), operations and hip and knee joints, prevention of venous tromboemboliy in patients after operations on abdominal organs, who are at risk of thromboembolic complications, prevention of venous tromboemboliy in patients at risk of such complications due to prolonged restriction of g phase during disease unstable angina or MI without ST segment elevation in order to prevent deaths, MI and refractory ischemia, MI with ST segment rise to prevent deaths, re-MI patients who are Term Birth Living Child Thrombolytic or in those who initially did not receive other forms of reperfusion therapy. The main pharmaco-therapeutic effects: Antithrombotic. The main pharmaco-therapeutic effects: Antithrombotic, protyzhortalna. Pharmacotherapeutic group.
אין תגובות:
הוסף רשומת תגובה